BERKELEY, Calif. and MAINZ, Germany, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics ...
Mainz Biomed partners with labor team to launch DNA-based ColoAlert® colorectal cancer screening in Switzerland, enhancing early detection efforts. Mainz Biomed N.V. has announced a strategic ...
Fintel reports that on February 14, 2025, Maxim Group initiated coverage of Mainz Biomed N.V. (NasdaqCM:MYNZ) with a Buy ...
Updated Screening Guidelines Ensure Broader Access to Colorectal Cancer Screening in GermanyBERKELEY, Calif. and MAINZ, ...
Mainz Biomed NV is a molecular genetics cancer diagnostic company. The firm is engaged in the developing of market-ready molecular genetic diagnostic solutions for life-threatening conditions.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Issuer: Mainz Biomed N.V. / Key word (s): Alliance Mainz Biomed Expands into Switzerland with labor team w 20.02.2025 / 14:01 CET/CEST The issuer is solely responsible for the content of this ...
Mainz Biomed (MYNZ) announced a strategic partnership with labor team w ag, a diagnostic laboratory based in Goldach, Switzerland. This ...
BERKELEY, Calif. and MAINZ, Germany, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed” or the "Company”), a molecular genetics diagnostic company specializing in the ...
BERKELEY, US – MAINZ, Germany – February 20, 2025 -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the“Company”), a molecular genetics diagnostic company specializing in the early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results